Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

August 8, 2024

Study Completion Date

August 8, 2024

Conditions

Refractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome

Interventions

DRUG

Fostamatinib

Given PO

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER